Kiralda

Gadobutrol, the active ingredient in Kiralda, is a Gadolinium-based contrast agent presented as a sterile injectable solution for intravenous use. It enhances magnetic resonance imaging by increasing signal intensity on T1‑weighted sequences, aiding diagnosis in a variety of clinical settings.

GNH USA supplies Kiralda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kiralda (gadobutrol) is used as a gadolinium‑based contrast agent to improve magnetic resonance imaging across several anatomical regions.

- Brain MRI: provides enhanced visualization of intracranial structures and pathology. - Spine MRI: improves delineation of the spinal cord, vertebrae and surrounding tissues. - Musculoskeletal MRI: increases contrast of joints, muscles and bone lesions. - Abdominal and pelvic MRI: enhances detection of lesions in liver, kidneys and pelvic organs. - Magnetic resonance angiography: facilitates clearer depiction of vascular anatomy.

Adverse reactions to gadobutrol may range from mild to severe. Monitoring patients during and after injection is recommended.

Common Side Effects: - Nausea - Headache - Warm sensation or flushing - Injection site pain or erythema - Dizziness - Mild hypotension

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Nephrogenic systemic fibrosis (especially in severe renal impairment) - Severe hypotension or cardiovascular collapse - Cardiac arrest (very rare) - Acute kidney injury

Use of gadobutrol requires careful assessment of patient-specific risk factors and proper handling of the product.

- Renal function assessment: evaluate glomerular filtration rate before administration. - History of allergic reactions: screen for prior contrast media hypersensitivity. - Pregnancy considerations: use only if clearly needed, as safety data are limited. - Pediatric use: dose should be calculated by the prescriber based on weight. - Severe renal impairment: avoid or use with extreme caution due to NSF risk. - Store at ambient temperature: keep in original container, protect from light and moisture.

Gadobutrol may interact with other agents that affect renal function or increase the risk of hypersensitivity.

Major Interactions (Avoid): - Concurrent use of other gadolinium agents: increased cumulative gadolinium exposure. - High‑dose iodinated contrast agents: additive renal stress. - Nephrotoxic drugs (e.g., aminoglycosides, amphotericin B): heightened risk of renal injury.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance of gadobutrol. - ACE inhibitors or ARBs: monitor renal function during co‑administration. - Metformin: consider temporary discontinuation in patients with impaired renal function.